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Abstract
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of Gram-negative bacterial
cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production
of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic
hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine
and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses.
We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid
A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-
presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL
when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the
immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative TH1
response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing
DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell
trafficking, activities which have important implications for the development of future vaccine adjuvants.
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Introduction
The goal of immunization is to generate specific and strong
immune responses against target antigens with minimal side
effects. In the past, most vaccines have been developed using live
attenuated or killed whole organisms that do not require
adjuvants, in some cases because they mimic natural infection
and inherently contain microbial immune modulators, including
TLR ligands. Subunit vaccines, consisting of a pathogen protein
with an immunostimulatory adjuvant, offer a distinct advantage
over live attenuated or heat killed vaccines, in that they do not
have the potential to be infectious, and therefore can be
administered to immunocompromised, as well as immunocompe-
tent people. However, unlike attenuated live vaccines, many
subunit vaccine antigens require adjuvants to enhance the strength
and duration of the immune response to these antigens which may
be weakly immunogenic on their own [1,2,3]. Until recently, salts
such as aluminum hydroxide and aluminum phosphate (alum)
were the only adjuvants in approved human vaccines in the USA.
Although alum is effective in boosting antibody responses,
achieving these responses requires repeated administration and
tend to be biased towards T helper (TH) 2, rather than TH1,
immunity [4]. However, effective vaccines against some of the
major causes of death worldwide (HIV, tuberculosis, malaria and
possibly influenza) require both humoral and T cell responses,
particularly TH1-mediated immunity. As a consequence, there is
much effort devoted to developing adjuvants that can promote
protective immunity through induction of enhanced and durable
antibody and TH1 responses.
It has long been known that LPS, contained in the outer
membrane of Gram-negative bacteria, is a potent stimulator of the
immune system, albeit toxic. A non-toxic derivative of LPS,
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Salmonella minnesota R595 by removal of the core carbohydrate
group, the phosphate from the reducing-end glucosamine, and the
acyl chain from the 39-position of the disaccharide backbone [5].
The resulting product demonstrates only ,0.1% of the inflam-
matory toxicity of its parent molecule, LPS [6,7]. Furthermore, it
promotes the differentiation of IFN-c secreting TH1 CD4+T cells,
and enhances immune responses to co-administered antigens.
MPLH combined with alum (AS04) is the adjuvant contained in
two approved vaccines (CervarixH, and FendrixH, both produced
by GlaxoSmithKline Biologicals (GSK), for human papilloma
virus and hepatitis B virus, respectively). GSK has also developed
liposomal (AS01) and oil-in-water (AS02) formulations containing
MPLH that are included in malaria [8] and tuberculosis [9]
vaccines that are currently in clinical trials. In addition, we are
evaluating MPLH in a stable oil-in-water emulsion (MPLH-SE) as
part of a leishmaniasis vaccine [10,11].
Detection of microbes by the mammalian immune system is
mediated by several families of pattern-recognition receptors,
including TLRs, and this recognition leads to the activation of
innate and adaptive immune responses [12]. TLRs, of which ten
are known to be functional in humans, are linked to the control of
bacterial and viral infections through one or more adaptor
proteins containing a Toll–interleukin 1 receptor domain. TLR4,
targeted by LPS and related molecules such as MPL, is unique
among the TLR as it induces two distinct signaling pathways
controlled by (i) MyD88/MAL which results in activation of
nuclear factor (NF)-kB for induction of a number of NF-kB-
dependent genes and inflammatory cytokines, and (ii) TRIF/
TRAM which induces production of type I interferons (IFN)
(reviewed in [13]). TLR4 also plays a non-redundant role in
eliciting DC maturation which is key in adjuvant-mediated
vaccine-antigen immunogenicity, since DC play a significant role
in priming naı ¨ve T cells and initiating potent immune responses
[14]. Recent studies have demonstrated that both MyD88 and
TRIF synergize for maximal DC activation [15].
In this study, we explored the advantages of a pure synthetic
hexaacylated lipid A derivative, glucopyranosyl lipid A (GLA),
over naturally-derived and more heterogenous MPL
[16,17,18,19]. We characterized MyD88- and/or TRIF-depen-
dent gene transcription profiles and kinetics induced by GLA on
mouse and human DC, and correlated mRNA transcript with
protein levels. In addition, we present data on the ability of GLA
to induce systemic innate responses in vivo, and promote TH1
responses to co-administered antigens.
Materials and Methods
Reagents
GLA (molecular weight 1763.5) was synthesized by Avanti Polar
Lipids (Alabaster, AL) or Albany Molecular Research, Inc.
(AMRI, Albany, NY). Purified detoxified lipid A (MPL, Salmonella
minnesota R595) (molecular weight 1525.1) was purchased from
Avanti Polar Lipids. LPS (Salmonella minnesota R595) was purchased
from Sigma-Aldrich (St Louis, MO). The structure and molecular
characteristics of GLA have been described previously [20].
Mice
Female C57BL/6 and BALB/c mice were purchased from
Charles River (Wilmington, MA) or Jackson Laboratories (Bar
Harbor, ME). Mice (6–12 wk of age) were maintained under
pathogen-free conditions in the animal facility at IDRI, and
treated in accordance with the guidelines of the IDRI Animal
Care and Use Committee.
Adjuvant Formulations
GLA and MPL were formulated as aqueous suspensions (AF) as
previously described [20]. Purity was assessed on samples at a
concentration of 50 mg/mL by high-pressure liquid chromatogra-
phy (HPLC) and mass spectrometry [21]. Mass spectrometry data
was collected by electrospray ionization in negative ion mode on a
Fourier Transform Ion Cyclotron Resonance Mass Spectrometer
(Bruker APEX Qe 47e). GLA-SE was prepared by mixing GLA
with the squalene oil phase (SE) [21] before mixing with the
aqueous phase and processing as previously described [20]. The
stock formulation contained GLA at 1 mg/mL in 10% oil and was
filter sterilized with a Millipore Steripak GP10 filter unit. GLA and
MPL formulations were tested for stability by Dynamic Light
Scattering (DLS) using a Malvern Zetasizer Nano [21]. Stability
testing was done for the following time points: Day of Manufacture
(DM); 1 and 2 wks; 1, 3, 6, 9 and 12 months. Concentration
testing was also done on GLA-SE by HPLC [20] and found to be
consistent through the formulation procedure (data not shown).
Cells
Mouse DC. Bone marrow-derived DC (BMDC) were
generated in vitro from the aspirated bone marrow from the
femurs of mice. Single cell suspensions were prepared, washed and
suspended at a concentration of 1610
6 cell/mL in complete
medium (RPMI 1640, 10% fetal bovine serum, 1% L-glutamine,
1% penicillin/streptomycin) supplemented with 20 ng/mL
recombinant mouse GM-CSF and 20 ng/mL IL-4 (PeproTech,
Rocky Hill, NJ). On day 3, DC were supplemented with 10 mL of
complete medium and GM-CSF. The non-adherent cell
population was used in experiments at day 5–7.
Human DC. Informed consent was obtained from all the
subjects and the study was approved by Western IRB, Seattle, WA.
Buffy coats were obtained from healthy volunteers and PBMC
were isolated by standard Ficoll-Hypaque density gradient
centrifugation. DC were generated from PBMC following either
adherenceon plastic orCD14+ positiveselectionfollowingstandard
methods which are briefly outlined below. Monocyte-derived DC
were generated by plastic-adherence of PBMC (15610
6 cells/well)
for 1 h in RPMI medium containing 1% fetal bovine serum. After
incubation, non-adherent cells were removed by three washes with
1x PBS and the remaining adherent cells were then cultured in
complete medium supplemented with GM-CSF (50 ng/mL) and
IL-4 (20 ng/mL) (both Invitrogen, Carlsbad, CA). On day 3, the
DC cultures received a supplemental dose of GM-CSF and IL-4.
Non-adherent and loosely adherent DC were collected and used in
the experiments after 5–7 days in culture. Alternatively, CD14+
monocytes were magnetically labeled with CD14 MicroBeads
(Miltenyi Biotec, Auburn, CA) and purified on a MACS separator
following the manufacturer’s protocol. The eluted fraction
containing the CD14+ cells were cultured at 0.5–1610
6 cells in
complete medium containing GM-CSF (50 ng/mL) and IL-4
(50 ng/mL) for 5 days prior to use in the experiments. DC
preparations contained ,95% DC, no CD14+ cells and ,2%
contaminatingB cellsasassessed bymorphology and FACS analysis
(data not shown).
Gene Expression in Response to TLR4 Agonists
Microarray. Cultured mouse BMDC (5610
5) were treated
with buffer, or TLR4 agonists GLA (0.5 mg/ml), MPL (0.5 mg/
mL), and LPS (40 ng/mL) for 4 h at 37uC. Total RNA was
extracted with an RNeasy kit (Qiagen, Valencia, CA), amplified
and biotinylated using the MessageAmp II aRNA amplification kit
(Applied Biosystems, Warrington, UK), hybridized to the mouse
inflammation 4x2K CustomArray (Combimatrix, Mukilteo, WA),
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Sunnyvale, CA). Comparative analysis of treated versus
untreated samples was done using BRB-ArrayTools software
(NCI). Statistical significance was determined by a two-sample
t-Test and a p-value ,0.001.
Branched DNA assay. Mouse BMDC and human
monocyte-derived DC (5610
4) were treated with 1 mg/mL of
the TLR4 agonists MPL, GLA and LPS, or buffer alone (control)
for 2–8 h at 37uC as specified in the legends. Cells were lysed and
mRNAs for GAPDH, IL-1a, IL-1b, IL-6, IL-12p40, TNF, CCL2,
CCL3, CCL4, CCL5, CCL7, CXCL1, CXCL10, IFN-b, IFIT-1,
MX1, PKR, G-CSF, ICAM-1, CD40, CD80, CD83, and/or
CCR7 were captured using the QuantiGene multiplex assay
(Panomics, Fremont, CA) according to the manufacturer’s
instructions. Transcript levels were quantitated using the
Luminex 200 system (LuminexCorp, Austin, TX) and analyzed
using the MasterPlex EX software (Miraibio, San Francisco, CA).
Cytokine/Chemokine ELISA
Mouse and human DC, and human PBMC were seeded at 2610
5
cells/well in complete RPMI medium, and stimulated for 4–24 h at
37uC with 0.001–1000 ng/mL of the TLR4 agonists as indicated in
the figure legends. Supernatants were collected and analyzed for IL-
1b, IL-6, IL-12p40, TNF, CCL4, CCL5, CCL7, CXCL10, and/or
IFN-b. These cytokine and chemokine levels were determined by
sandwich ELISA using paired antibodies (eBioscience, San Diego,
CA, BD Biosciences, San Jose, CA, or Invitrogen), or by using a
custom Luminex-based multiplex immunoassay kits (Procarta
Cytokine Assay Kit: Affymetrix, Santa Clara, CA). Briefly, culture
supernatants were incubated with polystyrene beads coated with
antibodies corresponding to the different cytokines, and developed
according to the manufacturer’s instructions. Bead size and
fluorescence were measured on a Luminex 200 and data was
analyzed using the Masterplex QT software (Miraibio).
Cell Marker Expression and Flow Cytometry
DC were incubated with 1–1000 ng/mL of TLR4 agonists for
either 24 h to determine DC cytokine expression or 48 h to
analyze DC surface marker expression, unless otherwise stated.
For TLR blocking experiments, DC were pre-incubated for 1 h at
37uC with 1 mg/mL of anti-TLR-2 (clone TL2.1), anti-TLR4
(clone HTA125), or IgG2a isotype control (clone eBM2)
(eBioscience). Briefly, DC maturation was determined by using
fluorochrome-conjugated antibodies that recognize following
surface molecules: CD11c, MHC Class II, CD86, and CD40
(mouse, eBioscience) and CCR7, CD80, CD83, CD86, and CD40
(human, eBioscience). DC were then fixed with Fix buffer (BD
Biosciences) and analyzed by flow cytometry or permeabilized and
further incubated with fluorochrome-conjugated antibodies for
intracellular cytokine (eBioscience). DC were characterized by
FSC vs SSC followed by gating on CD11c and MHC class II
expression. Data were collected on an LSRII flow cytometer and
expression of various markers was assessed using FlowJo (TreeStar,
Ashland, OR) or FACSDiva
TM (BD Biosciences) analysis software.
T cell Stimulation Assay
BMDC (5610
4) from C57BL/6 mice were incubated for 48 h
with 50–5000 ng/mL ID83 plus either media, or aqueous GLA or
MPL at 1, 5 and 20 ng/mL, and CD4+ T cells (2610
5) from
splenocytes of ID83-immunized mice purified over MACS column
Figure 1. Stability of GLA adjuvant formulations. (A) Differences between the synthetic GLA (structure in grey) and naturally
occurring endotoxins. (i) – The GLA has no attached residues on the hydroxyl; endotoxins have some or many sugars attached to
this site. (ii) – There is no second phosphate on GLA; naturally occurring lipid A cores have two phosphates with one attached to
site ‘‘ii’’. (iii) – The chain attachment positions, number, and lengths are defined. Naturally occurring species can have a variety of
attachment sites, number of chains and the number of carbons within the chains vary. (B) HPLC chromatograms of GLA and MPL. Arrows
indicate the predominant acylated form: hexa- (GLA) and pentaacylated form (MPL). (C) Mass spectrometry profiles of GLA and MPL. (D) Particle size
over time of GLA-AF and GLA-SE. As controls, stability of -SE and MPL-SE are shown. Data presented are the mean 6 SD of 3–4 different lots of
adjuvant formulations.
doi:10.1371/journal.pone.0016333.g001
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were analyzed for IFN-c by ELISA (eBioscience).
Systemic Effects of Adjuvant Formulations
C57BL/6 mice were injected intramuscularly (50 mL per
quadriceps) three times, two weeks apart with 8 mg ID83 [22]
antigen either formulated with GLA-SE (1, 5 or 20 mg), MPL-SE
(1, 5 or 20 mg) or SE alone.
Serum proteins. Sera were collected at time 0 and 4 h following
the first injection and tested for the presence of IL-12p40, TNF, IL-6,
MCP-1, CCL5, CXCL10 by multiplex ELISA as described above.
T helper cell priming. Seven days after the last immunization,
splenocytes were plated at 2610
5 in complete medium, and incubated
for 72 h with 10 mg ID83. Supernatants were collected and analyzed
for IFN-c cytokine production by ELISA (eBioscience).
Statistical Analysis
Statistical analysis of the data was performed using the Student t
Test using GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego, CA).
Results
Formulations of Synthetic Glucopyranosyl Lipid Adjuvant
GLA is a synthetic lipid A derivative composed of a disaccharide
backbone, a single phosphate group, and six C14 acyl chains [20]
(Fig. 1A). Several differences exist between synthetic
GLA and naturally occurring endotoxins including (i) the
absence of attached residues on the hydroxyl, (ii) the
absence of a second phosphate on GLA, and (iii) defined
position, number and lengths of chain attachments and
carbon number (Fig. 1A). Naturally occurring species
can have a variety of attachment sites, number of chains
and the number of carbons within the chains vary. HPLC
profile of GLA confirmed the presence of a single peak
corresponding to the hexaacylated form of the molecule by HPLC
(Fig. 1B) and mass spectrometry (Fig 1C). In contrast, MPL
showed one major peak corresponding to the pentaacylated form
(Fig. 1B–C), a minor peak corresponding to a hexaacyl form, and
three additional minor peaks with higher and lower molecular
weight illustrating the more heterogeneous composition of MPL.
GLA and MPL were prepared as an aqueous (-AF) or oil-in-water
Figure 2. BMDC gene expression in response to TLR4 agonists. BMDC were stimulated for 4 h with GLA-AF (0.5 mg/mL), MPL-AF (0.5 mg/mL),
or LPS (40 ng/mL). Total RNA was extracted, amplified, biotinylated, and hybridized to the mouse inflammation 4x2K CustomArray (Combimatrix).
Comparative analysis of treated versus untreated samples was done using BRB-ArrayTools software (NCI). Statistical significance was determined bya
random-variance t-test and a p-value ,0.001. A 2.5-fold change above untreated samples was considered significant upregulation. Selected genes
were partitioned into distinct categories and displayed in the heat-map for each set.
doi:10.1371/journal.pone.0016333.g002
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elicits more robust TH1 immune responses [22,23,24,
25,26]. However, the oil-content prohibits the use of the
SE formulation for in vitro evaluation, therefore GLA
was formulated and tested in vitro in an aqueous
formulation. GLA-AF and GLA-SE showed particle sizes
averaging 89.763.4 and 110.763.0, respectively (Fig. 1D). In
comparison, lots of MPL-SE averaged 117.262.7.
BMDC Responses to Synthetic Glucopyranosyl Lipid
Adjuvant GLA
Adjuvants activate innate immunity by inducing cytokine and
chemokine expression by DC and participate in the maturation of
these cells [27,28]. We recently reported that murine RAW264.7
and human MM6 monocyte/macrophage cell lines responded to
synthetic lipid A stimulation in vitro by secreting TNF, IL-6, and
CXCL10/IP-10 [20,23], in a TLR4 dependent fashion [23]. To
extend our understanding of the genes stimulated by GLA, and in
comparison to other TLR4 ligands, BMDC were stimulated for
4 h and the isolated mRNA were amplified and hybridized to a
custom mouse inflammation array (CombiMatrix) containing 840
genes. Global normalization was used to median the center of the
log ratios on each array followed by random-variance t-test
between treated samples (TLR agonist stimulated) and untreated
samples (buffer control). Genes were considered significantly
upregulated in treated samples if their p value was less than
0.001 and whose expression was at least 2.5-fold above untreated
samples. RNA transcripts for pro-inflammatory cytokines, chemo-
kines, and corresponding inducible genes, particularly TNF, IL-6,
IL-12b, were up-regulated by GLA and MPL stimulation when
compared to buffer control. RNA transcripts for the TRIF-
dependent type I interferon-inducible genes and transcription
factors were also upregulated (Fig. 2). Kinetic studies were further
performed on a subset of 8 genes that are activated by the MyD88
and/or TRIF pathway (Fig. S1, upper panel) and 6 genes
activated through the TRIF pathway only (lower panel). At the
agonist concentration tested (1 mg/mL), GLA and MPL showed
similar transcript levels and kinetics for all the RNA tested.
Responses to stimulation with equivalent concentration of LPS
were higher for all the MyD88- and/or TRIF-dependent activated
genes tested, with the exception of CCL3 and CCL4 (similar
levels). TRIF only-dependent genes showed similar transcript
levels and kinetics (4 h and 8 h, but not at 2 h) in response to LPS
compared to GLA stimulation, with the exception of G-CSF
which showed increased levels of RNA transcripts.
At the protein level, BMDC stimulated with GLA or MPL
showed similar dose-dependent increases in IL-12p40, TNF, and
IL-6 pro-inflammatory cytokines (Fig. 3A). LPS appeared 10-100-
Figure 3. Dose-dependent activation and maturation of BMDC in response to GLA stimulation. BMDC were stimulated with 0.01–
1000 ng/mL of GLA-AF, MPL-AF, LPS or equivalent volumes of AF. (A) IL-12p40, TNF, and IL-6 cytokine levels in culture supernatants after 24 h. (B)
Percentage of CD86
+, CD40
+, and MHC Class II
+ DC cells determined within the CD11c
+ gate after 48 h of incubation with the TLR4 agonists (C57BL/6,
left panels; BALB/c, right panels). (C) DC were pulsed with media or ID83 antigen (50 ng/mL), without or with 1 ng/mL of TLR4 agonist, washed and
further incubated with antigen-specific CD4 T cells for 48 h. IFN-c levels in culture supernatants were measured by ELISA. Data shown are
representative of two independent experiments.
doi:10.1371/journal.pone.0016333.g003
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responses were observed with the buffer control (AF). In addition to
the production of cytokines and chemokines, a hallmark of DC
activation is the up-regulation of co-stimulatory molecules on the cell
surface and increased antigen presentation capability. Therefore, we
characterized BMDC surface expression of MHC class II, CD40 and
CD86 in response to GLA stimulation in two mouse strains (C57BL/
6, BALB/c) by flow cytometry. GLA induced a dose-dependent
increase in CD40 and CD86 on the cell surface of DC from both
mousestrains,whileitfailedtofurtherincreaseMHCclassIIonthese
cells (Fig. 3B). No major differences were observed between GLA,
MPL and LPS (tested at 10 ng/mL) potency at regulating the three
surface molecules tested. Finally, to address the effect of GLA on DC-
mediated antigen presentation, we used a novel recombinant
subunit vaccine antigen called ID83 which combines three
antigens linked in tandem belonging to families of
Mycobacterium tuberculosis proteins associated with
virulence (Rv2608, Rv3620) or latency (Rv1813), and which
when combined with various TLR agonists have individ-
ually and fused together elicited protection against
aerosolized M. tuberculosis [22,29]. BMDC were pulsed with
or without the model antigen ID83 in the absence or presence of
1–20 ng/mL of TLR4 agonist, and were then cultured for 48 h with
CD4+ T cellspurified fromthesplenocytes of ID83 immunized mice.
DC pulsed with 50 ng/mL of ID83 in the presence of 1 ng/ml GLA
induced significantly (P,0.05) higher IFN-c secretion by CD4 T
cells, while the addition of similar concentrations of MPL or LPS had
no effect (Fig. 3C). No effect of GLA was observed at higher antigen
concentrations (500–5000 ng/mL) (data not shown). This finding
further supports the role of GLA in enhancing antigen presentation
by DC, especially at low antigen concentration.
Rapid Activation of Dendritic Cells to Synthetic GLA
We next characterized the in vivo local and systemic effects of the
GLA adjuvant in a squalene-based oil-in-water emulsion (GLA-SE),
when co-administered with ID83 [22]. C57BL/6 mice were
injected with ID83 i.m. three times two weeks apart with adjuvant
doses of 1, 5 and 20 mg of GLA-SE or MPL-SE along with relevant
Figure 4. Rapid activation of dendritic cells in response to GLA. C57BL/6 mice (n=6) were immunized 3x, 2 wks apart with ID83 antigen
co-administered with 1, 5 or 20 mg of GLA-SE or MPL-SE. Control groups included saline, ID83, and ID83+SE. (A) Mice were bled before (time 0) and
4 h after the first injection. Innate cytokine levels of IL-12p40, TNF, IL-6, MCP-1, CCL5 and CXCL10 were determined by Luminex.
doi:10.1371/journal.pone.0016333.g004
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cytokine and chemokines secretion plays a vital role in recruitment
and activation of innate and effector immune cells, such as
monocytes, macrophages, DC and T cells, we determined serum
innate cytokine and chemokine responses 4 h following the first
injection. Both GLA-SE and MPL-SE induced high cytokine
(TNFa, IL-12p40, IL-6) and chemokine (MCP-1, CCL5, CXCL10)
responses compared to saline, ID83 and ID83+SE controls (Fig. 4).
These responses were dose-dependent and showed the highest
responses at 20 mg TLR4 agonist immunization. There were no
statistical differences between GLA-SE and MPL-SE induced TNF
or IL-6 responses, while higher levels of IL-12p40 were measured in
response to 5 mg and 1 mg of GLA-SE compared to equivalent
amounts of MPL-SE (P,0.01 and P,0.05, respectively). Similarly,
an increase in levels of MCP-1, CCL5 and CXCL10 were observed
with 5 mg and/or 1 mg of GLA-SE compared to MPL-SE. Levels of
IL-10, a regulatory cytokine, was below the limit of detection for all
groups tested (data not shown).
GLA Promotes a TH1-type Response
To determine the effect of GLA on adaptive immune T cell
responses, mice were injected with ID83 i.m. three times
two weeks apart with adjuvant doses of 1, 5 and 20 mgo f
GLA-SE or MPL-SE along with relevant controls,a n d
splenocytes were collected from mice ten days after the third
immunization and incubated with or without ID83 in vitro for 72 h.
The levels of TH1/TH2 and regulatory cytokines (IFN-c, TNF/
IL-5, IL-13 and IL-10, respectively) in culture supernatants were
determined by using a Luminex assay. As previously observed with
a different vaccine [22], injection of the antigen in SE resulted in
strong TH2-biased immune responses characterized by high levels
of IL-5 and IL-13 (P,0.05 compared to ID83 alone) induction and
the absence of IFN-c and TNF (Fig. 5). In contrast, GLA-SE and
MPL-SE had measurable adjuvant effects on the priming of ID83-
specific T cells, with a strong skewing towards a TH1-type immune
response characterized by elevated levels of IFN-c and TNF and
absence of the TH2 cytokines IL-5 and IL-13, as compared with SE
Figure 5. GLA promotes a TH1-type response. C57BL/6 mice (n=6) were immunized 3x, 2 wks apart with ID83 antigen co-
administered with 1, 5 or 20 mg of GLA-SE or MPL-SE. Control groups included saline, ID83, and ID83+SE. Splenocytes were harvested
10 days following the third immunization and stimulated in vitro with ID83 for 72 h. Levels of TH1 (IFN-c, TNF), TH2 (IL-5, IL-13) and regulatory (IL-10)
cytokines in culture supernatants were determined by multiplex ELISA (Luminex). Data shown are mean 6 SD of triplicate wells, and are
representative of two independent experiments. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0016333.g005
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at 1 mg compared to (P,0.05). Furthermore, the regulatory
cytokine IL-10 was detected only in mice that were immunized
withID83 formulated withSE,butnot GLA-SE orMPL-SE (Fig. 5)
Enhanced Potency of GLA on Human Innate Immune
Responses
Structure-function analysis of synthetic lipid A derivatives
indicates that the length and number of acylated chains are
critical for signaling through TLR4 and activating human, but not
mouse, innate immune responses [30,31,32]. Therefore, we
characterized the activity of hexaacylated lipid A GLA on human
monocyte-derived DC at the RNA and protein levels, and
compared it to MPL, a mixture of penta, hexa and hepta-acyl
chains. Monocyte-derived DC from healthy human donors were
stimulated with 1 mg/mL of GLA, MPL and LPS, and RNA
transcript levels of MyD88- and/or TRIF- dependent or TRIF-
dependent only genes were quantified using the QuantiGene
assay. Lower levels of RNA transcripts were observed in human
DC stimulated with MPL when compared to GLA or LPS, for
genes of the MyD88- and/or TRIF-dependent pathway (Fig. 6A
top panel), while no differences in transcript levels were seen in
Figure 6. Kinetic of human DC gene expression in response to TLR4 agonist stimulation. DC were stimulated with 1 mg/mL of GLA-AF,
MPL-AF, or LPS. (A) RNA transcripts for a panel of MyD88- and/or TRIF-dependent genes (upper panel), TRIF-dependent only genes (middle panel), or
genes associated with DC maturation (lower panel) were captured after 2, 4, and 8 h of stimulation using the QuantiGene multiplex assay. (B) Protein
levels were determined after 4, 8, and 24 h stimulation for a subset of molecules in culture supernatants by ELISA. Data shown are the mean 6 SD of
duplicate wells, and are representative of DC from two blood donors. Difference significance between GLA-AF and MPL-AF groups at a given time
point were determined by unpaired Student’s t-Test, P,0.05 (*).
doi:10.1371/journal.pone.0016333.g006
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induce IL-1a, and up-regulated IL-1b, IL-12p40, TNF, CCL3,
and CCL4 in human DC. Genes activated through TRIF only
showed RNA transcripts levels mostly similar between GLA and
MPL, with the exception of lower levels of CCL5 in response to
MPL activation in human DC (Fig. 6A middle panel). TLR4
agonists induced higher levels of CCL5, CXCL10, IFIT-1, and
MX1 transcripts in human compared to mouse DC (Table 1). To
ensure that differences in transcript levels observed in response to
GLA and MPL activation were not due to differences in kinetics,
human DC were incubated with the TLR4 agonists for 2–8 h.
Transcript levels of genes from the MyD88- and/or TRIF-
dependent axis at all three time points were higher in response to
GLA activation when compared to the corresponding time points
in response to MPL (Fig. 6A). Transcripts levels of TRIF-
dependent only CCL5 and IFN-b were higher in the GLA groups
at all time points, however the highest IFN-b levels were observed
early after stimulation (2 h) and declined at 4 and 8 h. Increased
levels of CXCL10, IFIT-1, MX1, and PKR in response to GLA
were observed only at 2 h when compared to MPL. At the protein
level, increases in molecule concentration were time-dependent
(4 h,8h ,24 h), and GLA versus MPL profiles correlated with
the RNA results (Fig. 6B).
Transcript levels of markers associated with DC maturation,
such as CD40, CD80, CD83, CCR7, and ICAM-1, were also
higher in response to GLA compared to MPL (Fig. 6A lower
panel). TLR4 agonist dose-dependency was further addressed by
characterizing human DC activation (IL-12p40, TNF) and
maturation (HLA-DR, CD40, CD83, CD86, CCR7) markers by
a range of doses (1 to 1000 ng/mL) using flow cytometry.
Increased mean fluorescence intensity (MFI) expression of all the
molecules tested in response to GLA stimulation was dose-
dependent, and at least 10-fold more MPL was needed to achieve
the same level of protein up-regulation (Fig. 7A–B). TLR-blocking
experiments confirmed that GLA signaled through TLR4, but not
TLR2 in human DC (Fig. 7C).
Finally, we demonstrated that GLA activated human PBMC in
a dose-dependent manner for the secretion of cytokines such as IL-
12p40, TNF, IL-6, IL-1b, IL-10, IL-17 and IFN-c (Fig. S2A) and
chemokines such as CCL4, CCL5, CCL7, and CXCL10 (Fig.
S2B). As with human DC, PBMC showed higher responses to
GLA than MPL. Both induced lower cytokine/chemokine levels
than LPS at comparable agonist concentration, with the exception
of CXCL10.
Discussion
The capacity of host DC to mount an effective early innate
immune response to adjuvants may significantly impact the overall
immunogenicity and efficacy of vaccines. Derivatives of LPS, a
TLR4 agonist, such as purified detoxified monophosphoryl lipid A
(MPLH) and synthetic GLA are either approved or being tested in
clinical trials as novel vaccine adjuvants for use in humans
[10,11,33] (Tom Dubensky, personal communication). Numer-
ous prior studies have corroborated our results and
reported that structural differences such as the degree of
phosphorylation, and number, position and length of acyl chains
can dramatically affect the signaling outcome [30,32,34,35,36,37].
The studies presented here provide insight into mouse and human
DC innate immune response profiles to the synthetic hexaacylated
lipid A GLA, at the mRNA and protein levels. We demonstrate
that, while GLA and a MPL purified from S. minnesota R595
induced similar dose- and time-dependent responses in mouse
BMDC, GLA was 10–100-fold more active than MPL, a
Table 1. DC gene expression in response to TLR4 stimulation.
Mouse Human
MyD88- and/or TRIF-dependent GLA
a MPL LPS GLA MPL LPS
IL-1a 5968
b 59631 1 8 686 603 608 60
IL-1b 15611 6 612 4 626 2 642 8 609 1 62
IL-6 209642 2 1 610 298652 4 6 644 7 603 1 3 67
IL-12p40 9607 601 3 601 8 615 603 1 62
TNF 13611 4 612 5 608 1 633 1 619 8 63
CCL3 (MIP-1a)8 619 617 619 6 623 5 621 0 5 65
CCL4 (MIP-1b)3 8 634 2 653 9 631 6 6 637 1 611 7 9 65
CXCL1 (KC) 23612 1 608 4 622 5 611 0 613 7 61
TRIF-dependent only
CCL2 (MCP-1) 8608 607 611 0 612 5 612 3 61
CCL5 (RANTES) ND
c ND ND 71969 185657 4 8 61
CXCL10 (IP-10) 57646 6 610 5665 1509652 1242674 1658694
IFNb 55654 7 644 8 602 4 612 602 8 61
IFIT-1 77698 5 627 0 604 4 9 628 353624 3 6 623
MX1 ND ND ND 52624 4 604 9 61
PKR 13611 3 601 1 601 2 601 0 601 2 60
G-CSF 76678 0 692 0 1 653 602 605 61
aMouse bone-marrow derived and human monocyte-derived DC (5610
4) were incubated with 1 mg/mL of MPL, GLA or LPS for 4 h in 96-well round bottom plates.
Transcript expression was determined using the QuantiGene multiplex assay. Data shown is representative of two independent experiments.
bmRNA fold increase upon TLR-4 stimulation compared to buffer control (and normalized to GAPDH). Mean 6 SD are shown.
cND, not done.
doi:10.1371/journal.pone.0016333.t001
Synthetic Glucopyranosyl Lipid Adjuvant
PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16333predominantly pentaacylated lipid A, on human monocyte-
derived DC. Finally, we show that when administered to mice in
a stable oil-in-water emulsion (SE), GLA-SE induced strong
systemic innate responses and priming of antigen-specific TH1
cells.
LPS molecules are complex glycolipids present in the outer
membrane of Gram-negative bacteria. The lipid A domain of LPS
consists of a disaccharide with acyl chains of variable length and
number and is mostly responsible for its endotoxic activity by
inducing pro-inflammatory cytokines and type I IFN through the
TLR4/MD-2/MyD88 and TLR4/MD-2/TRIF pathways, re-
spectively[13,31,38]. Detoxification of LPS from S. minnesota R595,
for example, was achieved by the removal of the core
carbohydrate group, the phosphate from the reducing-end
glucosamine, and the acyl chain from the 39-position of the
disaccharide backbone [5]. The resulting molecule MPLH retained
only ,0.1% of the inflammatory toxicity of its parent LPS
molecule [7,39], and was initially shown to preferentially signal
through the TRIF rather than the MyD88 pathway in mouse
macrophages [35], though subsequent studies demonstrated that
MPL signals through both MyD88 and TRIF[40]. GLA, which
also lacks the second phosphate group, showed reduced endotoxi-
city compared to LPS, and induced levels of BMDC innate
immune responses comparable to MPL, respectively (Fig. 2–3, S2,
Table 1). Similarly to MPL [35], GLA signaled less efficiently than
LPS through the MyD88/MAL-dependent pathway, but fully
retained the ability to signal through TRIF/TRAM.
Depending on the mammalian species, the activities of different
types of lipid A can differ markedly at the TLR4/MD-2 complex.
While LPS and hexaacylated lipid A function as agonists in most
species, tetraacylated lipid IVa and Eritoran are agonists in mice,
and antagonists in humans and non-human primates [30,31].
Furthermore, a synthetic pentaacylated lipid A has also been
shown to lack bioactivity on HEK293T cells transfected with
human TLR4/MD-2 and on human PBMC [32]. Differences in
crystal structure of human TLR4/MD-2/LPS [36] and TLR4/
MD-2/lipid IVa [41] or TLR4/MD-2/Eritoran [42] complexes
recently shed light on the molecular and spatial interactions
between TLR4/MD-2 with agonist, and antagonists, respectively.
These studies showed that four acyl chains (Eritoran, lipid IVa)
Figure 7. Dose-dependent activation and maturation of human DC in response to GLA stimulation. Human monocyte-derived DC were
incubated with 1, 10, 100, and 1000 ng/mL of GLA-AF or MPL-AF, or 1000 ng/mL of LPS. Levels of cell surface co-stimulatory molecules and
intracellular cytokines were determined by flow cytometry. (A) IL-12p70 and TNF mean fluorescence fold (MFI) change over AF control at 12 h post-
stimulation. (B) HLA-DR, CD40, CCR7, CD83, and CD86 co-stimulatory molecules MFI change over AF control at 48 h post-stimulation. (C) CD86
expression on DC stimulated with 100 ng/mL GLA-AF or -AF for 48 h in the presence of 1 mg/mL of anti-TLR-2, anti-TLR4, or IgG2a isotype control
antibody. Data shown are the mean 6 SD (n=3, DC cultures from different blood donors), and representative of two independent experiments.
doi:10.1371/journal.pone.0016333.g007
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dimerization and lacked agonistic activity [34,41]. In contrast, in
the case of the hexaacylated LPS from E. coli, accommodating a
fifth acyl chain in the MD-2 pocket resulted in displacement of the
glucosamine backbone and reposition of the phosphate groups
which interact with positively charged residues on the TLR4/
TLR4* dimers. The sixth acyl chain also interacts with the TLR4/
TLR4* dimers and further contribute to the stabilization and
agonistic activity of the complex [36]. Consistent with these
previous observations, we show here that the pure hexaacylated
lipid A GLA was bioactive on human DC and PBMC, resulting in
DC innate immune responses, maturation and enhanced antigen-
presentation, while the predominantly pentaacylated MPL was 10
– 100-fold less effective (Fig. 6, 7, and S2). Unlike a synthetic
pentaacylated molecule which was completely inactive [32], MPL
retained some agonistic activity likely due to the presence of some
hexaacylated molecules as shown by HPLC and mass spectrom-
etry (Fig. 1A–B). Rallabhandi et al. reported a 20 – 90% decreased
cytokine level by adherent PBMC in response to Shigella flexneri 2a
(a mixture of hexa, penta, and predominantly tetraacylated lipid
A) than to E. coli (predominantly hexaacylated lipid A) LPS [32]
further illustrating the importance of using hexaacylated lipid A
derivatives when it comes to humans. Because GLA lacks one
phosphate group, it still remains several orders of magnitude less
endotoxic than its parent molecule LPS (Fig. S2), and is safer to
use in humans. TLR4 polymorphisms resulting in decreased
cytokine production in response to LPS [32] have been reported to
affect 6–10% of the population. However, it remains to be shown
if responses to GLA would also be decreased in these individuals.
Protective immunity to tuberculosis (TB) is conferred by IFN-c
producing TH1 CD4 and effector CD8 T cells [43]. Recently,
TLR4 agonists, including GLA, have been shown to induce potent
TH1-biased immune responses [20,22,23,24]. In the current study,
we observed a correlation between systemic innate responses,
enhanced antigen-presentation and TH1 priming. Particular,
innate pro-inflammatory cytokines and chemokines that are
involved in recruitment of antigen presenting cells and effector
T cells are enhanced following immunization with ID83 (TB
fusion vaccine antigen) formulated with GLA-SE. For example,
IL-12p40 is a chemoattractant for recruiting macrophages to the
site of infection, but also promotes migration of activated DC [44],
supporting our findings that GLA enhances TH1-biased immune
responses.
Altogether, the data presented here support the adjuvant activity of
GLA both in vitro and in vivo, and provide mechanistic evidence for the
protective immune responses elicited by GLA-containing vaccines in
animal models of tuberculosis and leishmaniasis [22,24]. Furthermore,
GLA presents the advantages of a pure synthetic component, stable in
aqueous and oil-in-water emulsions, fully active on human DC and
PBMC, that has already been scaled up and cGMP manufactured, and
was recently tested in a Phase I clinical trial for seasonal influenza
where it was shown to be well tolerated and immunogenic
(personal communication Tom Dubensky).
Supporting Information
Figure S1 BMDC gene expression in response to TLR4
agonist stimulation. BMDC were stimulated for 2, 4, and 8 h
with 1 mg/mL of GLA-AF, MPL-AF, or LPS. RNA transcripts for
a panel of MyD88- and/or TRIF- or TRIF-dependent only genes
were captured using the QuantiGene multiplex assay. Data shown
are the mean 6 SD of duplicate wells, and are representative of
three independent experiments.
(TIF)
Figure S2 PBMC immune responses to TLR4 agonists.
PBMC from healthy human donors were stimulated with 0.001 to
1000 ng/mL of TLR4 agonists for 24 h. Multiplex assays were
then performed on sample supernatants, focusing on cytokines and
chemokines that influence TH cell responses. Data shown are the
mean 6 SD of duplicates wells, and are representative of three
independent experiments. (A) Secretion of cytokines. (B) Secretion
of chemokines.
(TIF)
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